Phase 2 study of RSLV-132 in patients with Systemic lupus erythematosus (SLE)
Latest Information Update: 17 Dec 2020
At a glance
- Drugs RSLV 132 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Resolve Therapeutics
- 17 Dec 2020 New trial record
- 09 Dec 2020 According to a Resolve Therapeutics media release, this study is planned for 2021.